title: How should we treat mild and moderate-severe Crohn's disease in 2017? A brief overview of available therapies.
authors.affiliation: a Division of Gastroenterology, Hepatology and Endoscopy , Brigham and Women's Hospital , Boston , MA , USA.
authors.forename: Rachel W
authors.initials: RW
authors.lastname: Winter
authors.affiliation: a Division of Gastroenterology, Hepatology and Endoscopy , Brigham and Women's Hospital , Boston , MA , USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Burakoff
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018579:Patient Selection; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D001688:Biological Products; D005765:Gastrointestinal Agents
keywords: Crohn’s disease; biologics; inflammatory bowel disease; therapeutics; treatment